Semaglutide is the active ingredient in Ozempic and Wegovy — GLP-1 receptor agonists with well-documented results for both type 2 diabetes management and weight loss. When branded supply ran critically short, the FDA placed semaglutide on its drug shortage list. That designation allowed state-licensed compounding pharmacies to legally produce versions of the drug under specific conditions.

Compounded semaglutide is not a generic. It's a pharmacy-prepared formulation that replicates the active ingredient but hasn't gone through the same FDA review and approval process as a branded drug. The shortage designation was the legal foundation that made widespread compounding possible.

That foundation shifted in 2025 and into 2026.

The FDA's position on compounded semaglutide has moved in stages, and the timeline matters.

The shortage period. While semaglutide remained on the shortage list, compounding was permitted under Section 503A (patient-specific compounding by licensed pharmacies) and Section 503B (outsourcing facilities producing larger batches). Thousands of telehealth platforms and compounding pharmacies operated under this framework.

The shortage resolution. In early 2025, the FDA determined that the semaglutide injection shortage had been resolved. Once a drug comes off the shortage list, the legal basis for widespread 503B compounding largely disappears. The FDA issued guidance making clear that most compounding pharmacies could no longer produce copies of branded semaglutide products at scale.

Where things stand in 2026. The FDA has continued enforcement activity against outsourcing facilities producing compounded semaglutide outside the narrower criteria that now apply. Patient-specific compounding under 503A can still occur in limited circumstances — particularly when a prescriber documents a clinical need the commercially available product can't meet, such as a documented allergy to an inactive ingredient. But the broad availability that defined 2023 and 2024 has contracted significantly.

The practical takeaway: if you're receiving compounded semaglutide in 2026, whether that prescription is legitimate depends heavily on the pharmacy's licensure, the prescriber's documentation, and whether the formulation meets current regulatory requirements.

This is the question most patients actually want answered. The honest answer has two parts.

The Active Ingredient Itself

The semaglutide molecule, when correctly formulated and dosed, has a well-established safety profile. Clinical trials for Wegovy and Ozempic involved tens of thousands of participants over multiple years. The known side effects — nausea, vomiting, diarrhea, constipation, and in rarer cases more serious events like pancreatitis or thyroid concerns — apply to semaglutide regardless of whether it comes from a branded manufacturer or a compounding pharmacy.

The molecule isn't the primary safety variable. The formulation and the source are.

The Compounding Quality Variable

This is where the risk diverges from branded products. Compounding pharmacies don't go through the same pre-market approval process as drug manufacturers, and quality can vary significantly between facilities. The FDA has issued multiple warning letters citing problems including incorrect potency (doses that are stronger or weaker than labeled), contamination concerns, and use of semaglutide salt forms (such as semaglutide sodium or acetate) rather than the base form used in approved products, which have not been evaluated for safety or efficacy in humans.

That last point deserves emphasis. Some compounded products in circulation have used semaglutide salts — compounds that are chemically distinct from the active ingredient in Ozempic and Wegovy. The FDA has explicitly flagged this as a safety concern because these forms have never been tested in clinical trials.

What a Reputable Compounding Source Looks Like

Not all compounding pharmacies operate the same way. Patients who received compounded semaglutide through a clinically supervised telehealth platform — with a licensed prescriber reviewing their health history and a pharmacy following USP standards — had a materially different experience than those who ordered from unvetted online sources.

Markers of a legitimate compounding arrangement include: pharmacy licensed in your state and compliant with USP 797 sterile compounding standards; a prescriber who reviewed your full health history before prescribing; clear labeling with dosage, lot number, and beyond-use date; no use of semaglutide salts or unapproved additives; and transparent communication about what's actually in the formulation.

If you were prescribed compounded semaglutide during the shortage and are still using it, your situation in 2026 depends on a few things.

Your prescriber's documentation. For a 503A pharmacy to legally continue filling your prescription, there generally needs to be a documented clinical reason why the commercially available product doesn't meet your needs. "Patient preference" is shakier ground than a specific clinical indication.

Your pharmacy's status. Ask directly whether the pharmacy is a 503A or 503B facility, and whether they've received any FDA warning letters. This is public information. A reputable platform will answer without hesitation.

The transition to branded products. Many patients have moved to Wegovy or Ozempic as supply has normalized. If cost is the barrier — and it's a real one — it's worth having a direct conversation with your provider about manufacturer savings programs, insurance coverage, or alternative GLP-1 options.

The platform and prescriber you use matter as much as the pharmacy. A few things worth looking for:

Board-certified provider review. Your intake should be reviewed by a licensed, board-certified provider — not just processed by an algorithm. They should be asking about your cardiovascular history, kidney function, personal or family history of thyroid cancer, and any medications that could interact with GLP-1 therapy.

HIPAA-compliant data handling. Your health information is sensitive. The platform should be explicit about its HIPAA compliance and data practices.

Ongoing clinical support. GLP-1 treatment isn't a one-time prescription. Dosing titration, side effect management, and monitoring are part of responsible care. A platform that disappears after the initial prescription isn't providing adequate clinical oversight.

Transparent sourcing. Ask which pharmacy your prescription is being sent to and whether that pharmacy is accredited. If a provider can't or won't answer that question, that's a red flag.

At JoeyMed, the model is built around exactly this kind of supervised care. A board-certified provider reviews your health intake, you receive a personalized treatment plan, and prescriptions are shipped discreetly to your home. The platform is HIPAA-compliant and offers 24/7 customer service — which matters when you have a question about a side effect at 11pm on a Thursday.

A few misconceptions keep circulating that are worth addressing directly.

"FDA-approved means safe." FDA approval means a drug went through rigorous review of safety and efficacy data. It doesn't mean zero risk. Every medication has a risk profile. The relevant question is whether the benefit outweighs the risk for your specific situation — which is exactly why provider review matters.

"Compounded means fake or dangerous." Compounding has a legitimate place in medicine. Patients who need a specific dose not available commercially, or who have allergies to inactive ingredients, can genuinely benefit from compounded formulations. The problem isn't compounding itself — it's compounding done poorly, at scale, outside the regulatory framework that ensures quality.

"The FDA ban means compounded semaglutide is illegal everywhere." Not accurate. The FDA's enforcement actions target large-scale outsourcing facilities producing copies of branded products without meeting post-shortage criteria. Patient-specific compounding under 503A, with proper clinical documentation, remains a legal option in specific circumstances.

"My compounded semaglutide is identical to Wegovy." It may contain the same active ingredient, but it hasn't gone through the same manufacturing quality controls, stability testing, or clinical trials. That doesn't automatically make it unsafe — but it does mean the certainty is lower.

If you're currently using or considering compounded semaglutide, here's a practical checklist:

1. Confirm your pharmacy's licensure. Verify it's licensed in your state and ask whether it has received any FDA warning letters.
2. Ask about the formulation. Specifically ask whether the product uses semaglutide base — the form used in approved products — or a salt form. If the answer is unclear, that's a problem.
3. Review your clinical documentation. Make sure your prescriber has documented a clinical rationale for compounded rather than branded semaglutide.
4. Have a conversation about branded alternatives. With supply more stable in 2026, branded options are more accessible than they were two years ago. Cost is a real factor, but it's worth exploring what's available.
5. Choose a platform with real clinical oversight. A licensed provider who reviews your health history, monitors your progress, and is reachable for follow-up isn't a bonus — it's the baseline.

Is compounded semaglutide legal in 2026? It depends on the circumstances. Patient-specific compounding under 503A remains legal when a licensed prescriber documents a clinical need that the commercially available product can't address. Large-scale production by 503B outsourcing facilities is no longer permitted under the shortage-based authorization that expired when the FDA resolved the semaglutide shortage. The legality of your prescription hinges on your prescriber's documentation and your pharmacy's compliance status.

What is the difference between semaglutide base and semaglutide salts? Semaglutide base is the active form used in FDA-approved products like Wegovy and Ozempic. Semaglutide salts — such as semaglutide sodium or acetate — are chemically different compounds that have not been tested in human clinical trials. The FDA has specifically warned that products using these salt forms haven't been evaluated for safety or efficacy, which is a meaningful distinction for patients.

How do I know if my compounding pharmacy is reputable? Look for state licensure, USP 797 compliance for sterile compounding, and a clean record with no FDA warning letters. You can search the FDA's warning letter database publicly. A reputable telehealth platform will be transparent about which pharmacy it uses and willing to answer direct questions about accreditation.

Can I switch from compounded semaglutide to Wegovy or Ozempic? Yes, and for many patients this transition is now more practical than it was during the shortage. Talk to your provider about dosing equivalence — titration schedules may differ — and ask about manufacturer patient assistance programs if cost is a concern.

What side effects should I watch for regardless of whether my semaglutide is compounded or branded? Known side effects include nausea, vomiting, diarrhea, constipation, and decreased appetite. More serious but less common concerns include pancreatitis, gallbladder problems, and a potential risk of thyroid C-cell tumors — which is why semaglutide is contraindicated for patients with a personal or family history of medullary thyroid carcinoma. These risks apply to the molecule itself, not just compounded versions.

Is telehealth a safe way to get GLP-1 treatment? It can be, when the platform uses board-certified providers, conducts a thorough health intake, and provides ongoing clinical support. The risk goes up with platforms that offer minimal oversight or skip the intake process entirely. The quality of the provider relationship matters as much as the medication source.

Does JoeyMed offer GLP-1 treatment? Yes. JoeyMed covers weight loss including GLP-1 medications as part of its telehealth platform. You complete an online health intake, a board-certified provider reviews your information, and you receive a personalized treatment plan with prescriptions shipped to your home. No insurance required, and the platform is fully HIPAA-compliant.

Compounded semaglutide isn't automatically safe or unsafe. The answer depends on the pharmacy's quality controls, the formulation used, the prescriber's clinical oversight, and whether the arrangement meets current regulatory requirements. In 2026, the regulatory environment has tightened considerably from the shortage-era peak — which means patients need to ask sharper questions about where their medication is coming from and whether their provider is genuinely supervising their care.

If you're evaluating your options for GLP-1 treatment, start with a platform that takes the clinical side seriously. You can learn more about how supervised weight loss care works at JoeyMed.